Francisco Velazquez work email
- Valid
- Valid
Francisco Velazquez personal email
Abzena is a bioconjugate- and biologics-focused CDMO/CRO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implementsinnovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Learn more at abzena.com.Specialties: antibody-drug conjugates (ADCs), payload-linker constructs for ADCs, synthetic organic chemistry, synthetic route optimization, medicinal chemistry, drug design, lead optimization, patent preparation – writing and proof reading, collaboration on interdisciplinary teams.
-
DirectorAbzena May 2020 - PresentSan Diego, California, Us• Leads Abzena’s team of talented scientist to supports its clients by providing top-quality services to pharmaceutical, and biotech companies as well as non-for profit, governmental, and academic research institutions.• Utilizes his experience in pharmaceutical industry to support Abzena’s clients to advance their research projects in the areas of Antibody-Drug Conjugates (ADCs), immuno-oncology, and other innovative approaches for treatment of cancer. -
Principal ScientistAbzena Jan 2017 - May 2020San Diego, California, Us• Project Lead on multiple Discovery Research Projects to support advancement of Antibody-Drug Conjugates (ADCs) into early clinical development• Supported Abzena’s clients in the design and synthesis of novel cytotoxic payloads and payload-linker constructs for ADCs, including camptothecins (i.e. exatecan, Dxd, deruxtecan), MMAE (i.e. vedotin), duocarmycins, maytansinoids (i.e. DM1, MayNMA) and other proprietary payloads.• Supported Development Projects for the validation of synthetic routes for preparation of APIs in development and synthesis of chemical impurities for validation of chemical processes for manufacturing of APIs.
-
Pharmaceuticals Professional │ Drug Discovery Medicinal Chemist │ Cmc Regulatory Support. Dec 2016 - Jan 2017• Supported preparation of various CMC regulatory documentation to support Module 3 Drug Substance and Drug Product regulatory submissions.• Interpret CMC regulatory requirements for pharmaceutical products.• Authored and reviewed scientific manuscripts for publication in peer reviewed scientific journals.
-
Associate Principal ScientistMerck Nov 2009 - Nov 2016Rahway, New Jersey, Us• Co-inventor of the novel spirocylic-containing HCV NS3/4A antiviral inhibitor (MK-8831) that was advanced into clinical development.• Utilized structure-based drug design to invent a novel class of structurally complex HCV NS3/4A antiviral inhibitors based on Grazoprevir scaffold and a unique P2-spirocyclic proline that enabled intellectual property protection.• Optimized synthetic routes for lead compounds in GPR120 program that supported PK-PD and toxicological assessments.• Collaborated with colleagues in pharmaceutical science group to identify alternative formulations to mask bitter taste of APIs leading to improvements in patient medication compliance. -
Associate Principal ScientistMerck Jul 2003 - Nov 2009Rahway, New Jersey, UsAssociate Principal Scientist• Utilized structure-based drug design to identify new chemical space that led to design and synthesis of a novel class of tricyclic indoles as HCV NS5B polymerase antiviral inhibitors resulting in program progression, strengthened IP space and delivery of two antiviral pre-clinical candidates.• Design and executed a strategy in collaboration with formulation group to evaluate different salt forms and formulations of HCV NS5B inhibitors with poor solubility to improve pharmacokinetic profile which allowed critical go/no-go decisions for pre-clinical candidates in the program.Senior Scientist• Co-inventor of the antiviral NARLAPREVIR. a second-generation HCV NS3 protease inhibitor advanced into clinical trials.• Designed and developed several lead series for novel antivirals in the HCV NS3 protease program including P1-P3 macrocycles, P3-cyclic sulfones series
Francisco Velazquez Skills
Francisco Velazquez Education Details
-
University Of IowaMedicinal And Natural Products Chemistry -
Universidad De GuadalajaraMedicinal Chemistry
-
Universidad De GuadalajaraPharmaceutical Chemistry
Frequently Asked Questions about Francisco Velazquez
What company does Francisco Velazquez work for?
Francisco Velazquez works for Abzena
What is Francisco Velazquez's role at the current company?
Francisco Velazquez's current role is Director at Abzena.
What is Francisco Velazquez's email address?
Francisco Velazquez's email address is fr****@****orp.com
What schools did Francisco Velazquez attend?
Francisco Velazquez attended University Of Iowa, Universidad De Guadalajara, Universidad De Guadalajara.
What skills is Francisco Velazquez known for?
Francisco Velazquez has skills like Drug Discovery, Drug Development, Lead Change, Organic Chemistry, Organic Synthesis, Drug Design, Medicinal Chemistry, Nmr, Lc Ms, Hplc, Chromatography, Chemistry.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial